Aberrant alternative splicing events in Parkinson's disease

Cell Transplantation

Volumn 22, Issue 4, 2013, Pages 653-661

  Fu, Ru Huei ^a,b   Liu, Shih Ping ^a,b   Huang, Shyh Jer ^a   Chen, Hung Jen ^a   Chen, Pin Ru ^b   Lin, Ya Hsien ^b   Ho, Yu Chen ^b   Chang, Wen Lin ^b   Tsai, Chang Hai ^a,c   Shyu, Woei Cherng ^a,b   Lin, Shinn Zong ^a,b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

Author keywords

Alternative splicing (AS); Cis regulatory elements; Parkinson's disease (PD); Trans acting splicing factors

Indexed keywords

ALPHA SYNUCLEIN; LEUCINE RICH REPEAT KINASE 2; MESSENGER RNA; SYNPHILIN 1; TAU PROTEIN; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; AMINO ACID COMPOSITION; AUTOSOMAL DOMINANT INHERITANCE; CARBOXY TERMINAL SEQUENCE; CHEMICAL STRUCTURE; EXON; GENE CONTROL; GENE DELETION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; MISSENSE MUTATION; NERVE CELL NECROSIS; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ALTERNATIVE SPLICING; ANIMALS; HUMANS; PARKINSON DISEASE; PROGNOSIS;

EID: 84876474260     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368912X655154     Document Type: Review

References (72)

1. Anthony, K.; Gallo, J. M. Aberrant RNA processing events in neurological disorders. Brain Res. 1338:67-77; 2010.
2. Beyer, K. a-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol. 112:237-251; 2006.
3. Beyer, K.; Domingo-Sabat, M.; Humbert, J.; Carrato, C.; Ferrer, I.; Ariza, A. Differential expression of a-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. Neurogenetics 9:163-172; 2008.
4. Black, D. L. Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem. 72:291-336; 2003.
5. Blencowe, B. J. Alternative splicing: New insights from global analyses. Cell 126:37-47; 2006.
6. Buratti, E.; Baralle, F. E. Influence of RNA secondary structure on the pre-mRNA splicing process. Mol. Cell. Biol. 24:10505-10514; 2004.
7. Campion, D.; Martin, C.; Heilig, R.; Charbonnier, F.; Moreau, V.; Flaman, J. M.; Petit, J. L.; Hannequin, D.; Brice, A.; Frebourg, T. The NACP/synuclein gene: Chromosomal assignment and screening for alterations in Alzheimer disease. Genomics 26:254-257; 1995.
8. Carvey, P. M.; Punati, A.; Newman, M. B. Progressive dopamine neuron loss in Parkinson's disease: The multiple hit hypothesis. Cell Transplant. 15:239-250; 2006.
9. Chung, K. K.; Zhang, Y.; Lim, K. L.; Tanaka, Y.; Huang, H.; Gao, J.; Ross, C. A.; Dawson, V. L.; Dawson, T. M. Parkin ubiquitinates the a-synuclein-interacting protein, synphilin-1: Implications for Lewy-body formation in Parkinson disease. Nat. Med. 7:1144-1150; 2001.
10. D'Agata, V.; Cavallaro, S. Parkin transcript variants in rat and human brain. Neurochem. Res. 29:1715-1724; 2004.
11. David, C. J.; Manley, J. L. Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged. Genes Dev. 24:2343-2364; 2010.
12. Dawson, T. M.; Dawson, V. L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302:819-822; 2003.
13. Devi, G. R.; Beer, T. M.; Corless, C. L.; Arora, V.; Weller, D. L.; Iversen, P. L. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin. Cancer Res. 11:3930-3938; 2005.
14. Di Fonzo, A.; Tassorelli, C.; De Mari, M.; Chien, H. F.; Ferreira, J.; Rohe, C. F.; Riboldazzi, G.; Antonini, A.; Albani, G.; Mauro, A.; Marconi, R.; Abbruzzese, G.; Lopiano, L.; Fincati, E.; Guidi, M.; Marini, P.; Stocchi, F.; Onofrj, M.; Toni, V.; Tinazzi, M.; Fabbrini, G.; Lamberti, P.; Vanacore, N.; Meco, G.; Leitner, P.; Uitti, R. J.; Wszolek, Z. K.; Gasser, T.; Simons, E. J.; Breedveld, G. J.; Goldwurm, S.; Pezzoli, G.; Sampaio, C.; Barbosa, E.; Martignoni, E.; Oostra, B. A.; Bonifati, V.; Italian Parkinson's Genetics Network. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur. J. Hum. Genet. 14:322-331; 2006.
15. Dredge, B. K.; Stefani, G.; Engelhard, C. C.; Darnell, R. B. Nova autoregulation reveals dual functions in neuronal splicing. EMBO J. 24:1608-1620; 2005.
16. D'Souza, I.; Poorkaj, P.; Hong, M.; Nochlin, D.; Lee, V. M.; Bird, T. D.; Schellenberg, G. D. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism- chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc. Natl. Acad. Sci. USA 96:5598-5603; 1999.
17. D'Souza, I.; Schellenberg, G. D. Determinants of 4-repeat tau expression. Coordination between enhancing and inhibitory splicing sequences for exon 10 inclusion. J. Biol. Chem. 275:17700-17709; 2000.
18. Engelender, S.; Kaminsky, Z.; Guo, X.; Sharp, A. H.; Amaravi, R. K.; Kleiderlein, J. J.; Margolis, R. L.; Troncoso, J. C.; Lanahan, A. A.; Worley, P. F.; Dawson, V. L.; Dawson, T. M.; Ross, C. A. Synphilin-1 associates with a-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet. 22:110-114; 1999.
19. Eyal, A.; Szargel, R.; Avraham, E.; Liani, E.; Haskin, J.; Rott, R.; Engelender, S. Synphilin-1A: An aggregationprone isoform of synphilin-1 that causes neuronal death and is present in aggregates from a-synucleinopathy patients. Proc. Natl. Acad. Sci. USA 103:5917-5922; 2006.
20. Farrer, M. J. Genetics of Parkinson disease: Paradigm shifts and future prospects. Nat. Rev. Genet. 7:306-318; 2006.
21. Fu, R. H.; Liu, S. P.; Ou, C. W.; Yu, H. H.; Li, K. W.; Tsai, C. H.; Shyu, W. C.; Lin, S. Z. Alternative splicing modulates stem cell differentiation. Cell Transplant. 18:1029-1038; 2009.
22. Grabowski, P. J.; Black, D. L. Alternative RNA splicing in the nervous system. Prog. Neurobiol. 65:289-308; 2001.
23. Grover, A.; De Ture, M.; Yen, S. H.; Hutton, M. Effects on splicing and protein function of three mutations in codon N296 of tau in vitro. Neurosci. Lett. 323:33-36; 2002.
24. Hackl, C.; Papazoglou, A.; Ganser, C.; Klein, A.; Prakash, N.; Wurst, W.; Nikkhah, G. Ectopic dopaminergic progenitor cells from En1(+/Otx2lacZ) transgenic mice survive and functionally reinnervate the striatum following transplantation in a rat model of Parkinson's disease. Cell Transplant. 19:1085-1101; 2010.
25. Hong, M.; Zhukareva, V.; Vogelsberg-Ragaglia, V.; Wszolek, Z.; Reed, L.; Miller, B. I.; Geschwind, D. H.; Bird, T. D.; McKeel, D.; Goate, A. Morris, J. C.; Wilhelmsen, K. C.; Schellenberg, G. D.; Trojanowski, J. Q.; Lee, V. M. Mutationspecific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282:1914-1917; 1998.
26. Hoyer, W.; Cherny, D.; Subramaniam, V.; Jovin, T. M. Impact of the acidic C-terminal region comprising amino acids 109-140 on a-synuclein aggregation in vitro. Biochemistry 43:16233-16242; 2004.
27. Humbert, J.; Beyer, K.; Carrato, C.; Mate, J. L.; Ferrer, I.; Ariza, A. Parkin and synphilin-1 isoform expression changes in Lewy body diseases. Neurobiol. Dis. 26:681-687; 2007.
28. Hutton, M. Missense and splice site mutations in tau associated with FTDP-17: Multiple pathogenic mechanisms. Neurology 56:S21-25; 2001.
29. Hutton, M.; Lendon, C. L.; Rizzu, P.; Baker, M.; Froelich, S.; Houlden, H.; Pickering-Brown, S.; Chakraverty, S.; Isaacs, A.; Grover, A.; Hackett, J.; Adamson, J.; Lincoln, S.; Dickson, D.; Davies, P.; Petersen, R. C.; Stevens, M.; de Graaff, E.; Wauters, E.; van Baren, J.; Hillebrand, M.; Joosse, M.; Kwon, J. M.; Nowotny, P.; Che, L. K.; Norton, J.; Morris, J. C.; Reed, L. A.; Trojanowski, J.; Basun, H.; Lannfelt, L.; Neystat, M.; Fahn, S.; Dark, F.; Tannenberg, T.; Dodd, P. R.; Hayward, N.; Kwok, J. B.; Schofield, P. R.; Andreadis, A.; Snowden, J.; Craufurd, D.; Neary, D.; Owen, F.; Oostra, B. A.; Hardy, J.; Goate, A.; van Swieten, J.; Mann, D.; Lynch, T.; Heutink, P. Association of missense and 5¢-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393:702-705; 1998.
30. Imai, Y.; Soda, M.; Takahashi, R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275:35661-35664; 2000.
31. Johnson, J.; Paisan-Ruiz, C.; Lopez, G.; Crews, C.; Britton, A.; Malkani, R.; Evans, E. W.; McInerney-Leo, A.; Jain, S.; Nussbaum, R. L.; Foote, K. D.; Mandel, R. J.; Crawley, A.; Reimsnider, S.; Fernandez, H. H.; Okun, M. S.; Gwinn- Hardy, K.; Singleton, A. B. Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation. Neurodegener. Dis. 4:386-391; 2007.
32. Kalbfuss, B.; Mabon, S. A.; Misteli, T. Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J. Biol. Chem. 276:42986-42993; 2001.
33. Kalivendi, S. V.; Yedlapudi, D.; Hillard, C. J.; Kalyanaraman, B. Oxidants induce alternative splicing of a-synuclein: Implications for Parkinson's disease. Free Radic. Biol. Med. 48:377-383; 2010.
34. Keren, H.; Lev-Maor, G.; Ast, G. Alternative splicing and evolution: Diversification, exon definition and function. Nat. Rev. Genet. 11:345-355; 2010.
35. Lee, F. J.; Liu, F.; Pristupa, Z. B.; Niznik, H. B. Direct binding and functional coupling of a-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15:916-926; 2001.
36. Lee, H. J.; Choi, C.; Lee, S. J. Membrane-bound a-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277:671-678; 2002.
37. Linazasoro, G. Cell therapy for Parkinson's disease: Only young onset patients allowed? Reflections about the results of recent clinical trials with cell therapy and the progression of Parkinson's disease. Cell Transplant. 15:463-473; 2006.
38. Luco, R. F.; Allo, M.; Schor, I. E.; Kornblihtt, A. R.; Misteli, T. Epigenetics in alternative pre-mRNA splicing. Cell 144:16-26; 2011.
39. Lynch, T.; Sano, M.; Marder, K. S.; Bell, K. L.; Foster, N. L.; Defendini, R. F.; Sima, A. A.; Keohane, C.; Nygaard, T. G.; Fahn, S.; Mayeux, R.; Rowland, L. P.; Wilhelmsen, K. C. Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology 44:1878-1884; 1994.
40. Matlin, A. J.; Clark, F.; Smith, C. W. Understanding alternative splicing: Towards a cellular code. Nat. Rev. Mol. Cell Biol. 6:386-398; 2005.
41. McCarthy, J. J.; Linnertz, C.; Saucier, L.; Burke, J. R.; Hulette, C. M.; Welsh-Bohmer, K. A.; Chiba-Falek, O. The effect of SNCA 3¢ region on the levels of SNCA-112 splicing variant. Neurogenetics 12:59-64; 2011.
42. McGlincy, N. J.; Smith, C. W. Alternative splicing resulting in nonsense-mediated mRNA decay: What is the meaning of nonsense? Trends Biochem. Sci. 33:385-393; 2008.
43. Michell, A. W.; Tofaris, G. K.; Gossage, H.; Tyers, P.; Spillantini, M. G.; Barker, R. A. The effect of truncated human a-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease. Cell Transplant. 16:461-474; 2007.
44. Moore, M. J.; Silver, P. A. Global analysis of mRNA splicing. RNA 14:197-203; 2008.
45. Mouradian, M. M. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 58:179-185; 2002.
46. Newman, A. J.; Nagai, K. Structural studies of the spliceosome: Blind men and an elephant. Curr. Opin. Struct. Biol. 20:82-89; 2010.
47. Paisan-Ruiz, C.; Jain, S.; Evans, E. W.; Gilks, W. P.; Simon, J.; van der Brug, M.; Lopez de Munain, A.; Aparicio, S.; Gil, A. M.; Khan, N.; Johnson, J.; Martinez, J. R.; Nicholl, D.; Carrera, I. M.; Pena, A. S.; de Silva, R.; Lees, A.; Martí-Massó, J. F.; Pérez-Tur, J.; Wood, N. W.; Singleton, A. B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44:595-600; 2004.
48. Pan, Q.; Shai, O.; Lee, L. J.; Frey, B. J.; Blencowe, B. J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 40:1413-1415; 2008.
49. Park, S. M.; Jung, H. Y.; Kim, T. D.; Park, J. H.; Yang, C. H.; Kim, J. Distinct roles of the N-terminal-binding domain and the C-terminal-solubilizing domain of a-synuclein, a molecular chaperone. J. Biol. Chem. 277:28512-28520; 2002.
50. Payton, J. E.; Perrin, R. J.; Woods, W. S.; George, J. M. Structural determinants of PLD2 inhibition by a-synuclein. J. Mol. Biol. 337:1001-1009; 2004.
51. Polymeropoulos, M. H.; Lavedan, C.; Leroy, E.; Ide, S. E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; Stenroos, E. S.; Chandrasekharappa, S.; Athanassiadou, A.; Papapetropoulos, T.; Johnson, W. G.; Lazzarini, A. M.; Duvoisin, R. C.; Di Iorio, G.; Golbe, L. I.; Nussbaum, R. L. Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047; 1997.
52. Ribeiro, C. S.; Carneiro, K.; Ross, C. A.; Menezes, J. R.; Engelender, S. Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by a-synuclein. J. Biol. Chem. 277:23927-23933; 2002.
53. Samii, A.; Nutt, J. G.; Ransom, B. R. Parkinson's disease. Lancet 363:1783-1793; 2004.
54. Schellenberg, M. J.; Ritchie, D. B.; MacMillan, A. M. PremRNA splicing: A complex picture in higher definition. Trends Biochem. Sci. 33:243-246; 2008.
55. Shehadeh, L. A.; Yu, K.; Wang, L.; Guevara, A.; Singer, C.; Vance, J.; Papapetropoulos, S. SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease. PLoS One 5:e9104; 2010.
56. Sherer, T. B.; Betarbet, R.; Stout, A. K.; Lund, S.; Baptista, M.; Panov, A. V.; Cookson, M. R.; Greenamyre, J. T. An in vitro model of Parkinson's disease: Linking mitochondrial impairment to altered a-synuclein metabolism and oxidative damage. J. Neurosci. 22:7006-7015; 2002.
57. Shimura, H.; Hattori, N.; Kubo, S.; Mizuno, Y.; Asakawa, S.; Minoshima, S.; Shimizu, N.; Iwai, K.; Chiba, T.; Tanaka, K.; Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25:302-305; 2000.
58. Shulman, J. M.; De Jager, P. L.; Feany, M. B. Parkinson's disease: Genetics and pathogenesis. Annu. Rev. Pathol. 6:193-222; 2011.
59. Soderstrom, K.; OMalley, J.; Steece-Collier, K.; Kordower, J. H. Neural repair strategies for Parkinson's disease: Insights from primate models. Cell Transplant. 15:251-265; 2006.
60. Spillantini, M. G.; Schmidt, M. L.; Lee, V. M.; Trojanowski, J. Q.; Jakes, R.; Goedert, M. a-Synuclein in Lewy bodies. Nature 388:839-840; 1997.
61. Suh, Y. H.; Checler, F. Amyloid precursor protein, presenilins, and a-synuclein: Molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol. Rev. 54:469-525; 2002.
62. Tan, E. K.; Shen, H.; Tan, J. M.; Lim, K. L.; Fook-Chong, S.; Hu, W. P.; Paterson, M. C.; Chandran, V. R.; Yew, K.; Tan, C.; Yuen, Y.; Pavanni, R.; Wong, M. C.; Puvan, K.; Zhao, Y. Differential expression of splice variant and wildtype parkin in sporadic Parkinson's disease. Neurogenetics 6:179-184; 2005.
63. Tsai, R. T.; Fu, R. H.; Yeh, F. L.; Tseng, C. K.; Lin, Y. C.; Huang, Y. H.; Cheng, S. C. Spliceosome disassembly catalyzed by Prp43 and its associated components Ntr1 and Ntr2. Genes Dev. 19:2991-3003; 2005.
64. Tsai, R. T.; Tseng, C. K.; Lee, P. J.; Chen, H. C.; Fu, R. H.; Chang, K. J.; Yeh, F. L.; Cheng, S. C. Dynamic interactions of Ntr1-Ntr2 with Prp43 and with U5 govern the recruitment of Prp43 to mediate spliceosome disassembly. Mol. Cell. Biol. 27:8027-8037; 2007.
65. Ueda, K.; Saitoh, T.; Mori, H. Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-Ab component of Alzheimer's disease amyloid. Biochem. Biophys. Res. Commun. 205:1366-1372; 1994.
66. Ule, J.; Stefani, G.; Mele, A.; Ruggiu, M.; Wang, X.; Taneri, B.; Gaasterland, T.; Blencowe, B. J.; Darnell, R. B. An RNA map predicting Nova-dependent splicing regulation. Nature 444:580-586; 2006.
67. Wahl, M. C.; Will, C. L.; Luhrmann, R. The spliceosome: Design principles of a dynamic RNP machine. Cell 136:701-718; 2009.
68. Wang, E. T.; Sandberg, R.; Luo, S.; Khrebtukova, I.; Zhang, L.; Mayr, C.; Kingsmore, S. F.; Schroth, G. P.; Burge, C. B. Alternative isoform regulation in human tissue transcriptomes. Nature 456:470-476; 2008.
69. Wang, G. S.; Cooper, T. A. Splicing in disease: Disruption of the splicing code and the decoding machinery. Nat. Rev. Genet. 8:749-761; 2007.
70. Yasuhara, T.; Date, I. Intracerebral transplantation of genetically engineered cells for Parkinson's disease: Toward clinical application. Cell Transplant. 16:125-132; 2007.
71. Yurek, D. M.; Flectcher, A. M.; Kowalczyk, T. H.; Padegimas, L.; Cooper, M. J. Compacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neurons. Cell Transplant. 18:1183-1196; 2009.
72. Zimprich, A.; Biskup, S.; Leitner, P.; Lichtner, P.; Farrer, M.; Lincoln, S.; Kachergus, J.; Hulihan, M.; Uitti, R. J.; Calne, D. B.; Stoessl, A. J.; Pfeiffer, R. F.; Patenge, N.; Carbajal, I. C.; Vieregge, P.; Asmus, F.; Müller-Myhsok, B.; Dickson, D. W.; Meitinger, T.; Strom, T. M.; Wszolek, Z. K.; Gasser, T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601-607; 2004.